The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

On safety, there was a case of interstitial lung disease (ILD), a side effect that has been seen with other ADCs using Daiichi Sankyo's deruxtecan payload, like AstraZeneca's Enhertu (trastuzumab ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

MoA All America Fund earns an Average Process Pillar rating. The main driver of the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average 10 ...